LONDON – Immatics Biotechnologies GmbH has closed a €34 million (US$46.1 million) Series D financing, enabling it to complete Phase III development of lead cancer vaccine IMA901 in renal cancer and complete all preparations for filing with the FDA and the European Medicines Agency. Read More

LONDON – Signs of neurodegeneration in a mouse model of Alzheimer’s disease can be halted with a compound that can be taken by mouth, a new study has shown. Read More

LONDON – GT Biologics Ltd. is poised to become a pioneer of the new drug class of live biotherapeutics after receiving orphan drug status from the FDA for Thetanix, a bacterial treatment for pediatric Crohn’s disease. Read More

LONDON – Poxel SA generated new patient data on its diabetes treatment Imeglimin, demonstrating it has a novel mechanism of action and showing the drug could be used in combination with existing orally administered Type II diabetes treatments. Read More

SHANGHAI – A much-awaited free trade zone in Shanghai may eventually create some opportunities for biotechs, but nothing will happen overnight. Read More

LONDON – Pharming Group NV has taken the opportunity to raise €12 million (US$16.2 million) in a private placement after institutional investors started to buy its shares in the market. Read More

HONG KONG – China’s biopharmaceutical industry has been built around hundreds of dedicated zones that enjoy a series of benefits from municipal, provincial and central governments. These biotech parks, often independently managed, seek to attract multiple companies from both China and abroad. Read More

• Kymab Ltd., of Cambridge, UK, said it notified the English Court that it will defend the UK patent proceedings brought by Tarrytown, N.Y.-based Regeneron Pharmaceuticals Inc. in respect of European patent EP1360287. Regeneron initiated the proceedings in September. Kymab said it will defend the UK patent action on the grounds of non-infringement and invalidity of the patent. Read More